Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kerry Lynn Reynolds, M.D.

Title
Institution
Department
Address
Phone

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Vokoun CW, Murphy MC, Reynolds KL, Haines MS. Case 1-2023: A 49-Year-Old Man with Hypokalemia and Paranoia. N Engl J Med. 2023 01 12; 388(2):165-175. PMID: 36630625.
    Citations:    Fields:    Translation:Humans
  2. Shi CR, Shaughnessy M, Sehgal K, Clark JR, Reynolds KL, Toyohara J, Chen ST. Successful rechallenge with pembrolizumab after case of progressive immunotherapy-related mucocutaneous eruption (PIRME), a Stevens-Johnson syndrome-like reaction. Int J Dermatol. 2023 Jan 11. PMID: 36628976.
    Citations:    Fields:    
  3. Sise ME, Wang Q, Seethapathy H, Moreno D, Harden D, Smith RN, Rosales IA, Colvin RB, Chute S, Cornell LD, Herrmann SM, Fadden R, Sullivan RJ, Yang NJ, Barmettler S, Wells S, Gupta S, Villani AC, Reynolds KL, Farmer J. Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis. J Immunother Cancer. 2023 Jan; 11(1). PMID: 36657813; PMCID: PMC9853261.
    Citations:    Fields:    
  4. Lee C, Drobni ZD, Zafar A, Gongora CA, Zlotoff DA, Alvi RM, Taron J, Rambarat PK, Schoenfeld S, Mosarla RC, Raghu VK, Hartmann SE, Gilman HK, Murphy SP, Sullivan RJ, Faje A, Hoffmann U, Zhang L, Mayrhofer T, Reynolds KL, Neilan TG. Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy. JACC CardioOncol. 2022 Dec; 4(5):660-669. PMID: 36636443; PMCID: PMC9830202.
    Citations:    
  5. Groha S, Alaiwi SA, Xu W, Naranbhai V, Nassar AH, Bakouny Z, El Zarif T, Saliby RM, Wan G, Rajeh A, Adib E, Nuzzo PV, Schmidt AL, Labaki C, Ricciuti B, Alessi JV, Braun DA, Shukla SA, Keenan TE, Van Allen E, Awad MM, Manos M, Rahma O, Zubiri L, Villani AC, Fairfax B, Hammer C, Khan Z, Reynolds K, Semenov Y, Schrag D, Kehl KL, Freedman ML, Choueiri TK, Gusev A. Germline variants associated with toxicity to immune checkpoint blockade. Nat Med. 2022 12; 28(12):2584-2591. PMID: 36526723.
    Citations:    Fields:    Translation:Cells
  6. Munsell MK, Fadelu T, Stuver SO, Baker KP, Glotzbecker B, Simmons JL, Reynolds KL, Patel AK. The utility of procalcitonin for diagnosing bacteremia and bacterial pneumonia in hospitalized oncology patients. J Cancer Res Clin Oncol. 2022 Nov 13. PMID: 36371720.
    Citations:    Fields:    
  7. Quinaglia T, Gongora C, Awadalla M, Hassan MZO, Zafar A, Drobni ZD, Mahmood SS, Zhang L, Coelho-Filho OR, Suero-Abreu GA, Rizvi MA, Sahni G, Mandawat A, Zatarain-Nicolás E, Mahmoudi M, Sullivan R, Ganatra S, Heinzerling LM, Thuny F, Ederhy S, Gilman HK, Sama S, Nikolaidou S, Mansilla AG, Calles A, Cabral M, Fernández-Avilés F, Gavira JJ, González NS, García de Yébenes Castro M, Barac A, Afilalo J, Zlotoff DA, Zubiri L, Reynolds KL, Devereux R, Hung J, Picard MH, Yang EH, Gupta D, Michel C, Lyon AR, Chen CL, Nohria A, Fradley MG, Thavendiranathan P, Neilan TG. Global Circumferential and Radial Strain Among Patients With Immune Checkpoint Inhibitor Myocarditis. JACC Cardiovasc Imaging. 2022 11; 15(11):1883-1896. PMID: 36357131.
    Citations:    Fields:    Translation:Humans
  8. Jacoby TV, Shah N, Asdourian MS, Thompson LL, Otto TS, LeBoeuf NR, Semenov Y, Dee EC, Reynolds KL, Chen ST. Dermatology evaluation for cutaneous immune-related adverse events is associated with improved survival in cancer patients treated with checkpoint inhibition. J Am Acad Dermatol. 2022 Sep 14. PMID: 36113616.
    Citations:    Fields:    
  9. Wang Q, Strohbehn IA, Zhao S, Seethapathy H, Strohbehn SD, Hanna P, Lee M, Fadden R, Sullivan RJ, Boland GM, Reynolds KL, Sise ME. Effect of Cancer Stage on Adverse Kidney Outcomes in Patients Receiving Immune Checkpoint Inhibitors for Melanoma. Kidney Int Rep. 2022 Nov; 7(11):2517-2521. PMID: 36531890; PMCID: PMC9751690.
    Citations:    
  10. Gupta S, Garcia-Carro C, Prosek JM, Glezerman I, Herrmann SM, Garcia P, Abudayyeh A, Lumlertgul N, Malik AB, Loew S, Beckerman P, Renaghan AD, Carlos CA, Rashidi A, Mithani Z, Deshpande P, Rangarajan S, Shah CV, Seigneux S, Campedel L, Kitchlu A, Shin DS, Coppock G, Ortiz-Melo DI, Sprangers B, Aggarwal V, Benesova K, Wanchoo R, Murakami N, Cortazar FB, Reynolds KL, Sise ME, Soler MJ, Leaf DE. Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI. J Immunother Cancer. 2022 09; 10(9). PMID: 36137651; PMCID: PMC9511654.
    Citations: 1     Fields:    Translation:Humans
  11. Gupta S, Strohbehn IA, Wang Q, Hanna PE, Seethapathy R, Prosek JM, Herrmann SM, Abudayyeh A, Malik AB, Loew S, Carlos CA, Chang WT, Beckerman P, Mithani Z, Shah CV, Renaghan AD, de Seigneux S, Campedel L, Kitchlu A, Shin DS, Coppock G, Lumlertgul N, Garcia P, Ortiz-Melo DI, Rashidi A, Sprangers B, Aggarwal V, Benesova K, Jhaveri KD, Cortazar FB, Weins A, Zuo Y, Mooradian MJ, Reynolds KL, Leaf DE, Sise ME. Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer. Kidney Int. 2022 10; 102(4):930-935. PMID: 35964800; PMCID: PMC9523226.
    Citations:    Fields:    Translation:Humans
  12. Tang K, Tiu BC, Wan G, Zhang S, Nguyen N, Leung B, Gusev A, Reynolds KL, Kwatra SG, Semenov YR. Pre-Existing Autoimmune Disease and Mortality in Patients Treated with Anti-PD-1 and Anti-PD-L1 Therapy. J Natl Cancer Inst. 2022 08 08; 114(8):1200-1202. PMID: 35188215; PMCID: PMC9360452.
    Citations:    Fields:    
  13. Asdourian MS, Shah N, Jacoby TV, Reynolds KL, Chen ST. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review. JAMA Dermatol. 2022 08 01; 158(8):933-941. PMID: 35612829.
    Citations:    Fields:    
  14. Asdourian MS, Shah N, Jacoby TV, Semenov YR, Otto T, Thompson LL, Dee EC, Reynolds KL, Chen ST. Development of multiple cutaneous immune-related adverse events among cancer patients after immune checkpoint blockade. J Am Acad Dermatol. 2023 Feb; 88(2):485-487. PMID: 35738514.
    Citations:    Fields:    
  15. Asdourian MS, Jacoby TV, Shah N, Thompson LL, Otto T, Semenov YR, LeBoeuf NR, Reynolds KL, Dewan AK, Chen ST. Morphologic characteristics of cutaneous immune-related adverse events in patients receiving immune checkpoint inhibitors combined with other anticancer therapies: A multicenter retrospective study. J Am Acad Dermatol. 2023 Feb; 88(2):474-476. PMID: 35724890.
    Citations:    Fields:    
  16. Jacoby TV, Otto TS, Asdourian MS, Shah N, Farcasanu M, Chang MS, Thompson LL, Reynolds KL, Chen ST. Association of pre-existing drug allergies with cutaneous immune-related adverse events among patients on immune checkpoint inhibitor therapy. Br J Dermatol. 2022 09; 187(3):424-426. PMID: 35290662.
    Citations:    Fields:    
  17. Tiu BC, Zubiri L, Iheke J, Pahalyants V, Theodosakis N, Ugwu-Dike P, Seo J, Tang K, Sise ME, Sullivan R, Naidoo J, Mooradian MJ, Semenov YR, Reynolds KL. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study. J Immunother Cancer. 2022 06; 10(6). PMID: 35705313; PMCID: PMC9204442.
    Citations:    Fields:    Translation:Humans
  18. Le TK, Brown I, Goldberg R, Taylor MT, Deng J, Parthasarathy V, Bordeaux ZA, Alphonse MP, Kwatra MM, Naranbhai V, Gusev A, Alhariri J, LeBoeuf NR, Reynolds KL, Cappelli LC, Naidoo J, Brahmer JR, Kang S, Semenov YR, Kwatra SG. Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study. J Invest Dermatol. 2022 11; 142(11):2896-2908.e4. PMID: 35605659.
    Citations:    Fields:    
  19. Asdourian MS, Shah N, Jacoby TV, Thompson LL, Otto T, Semenov YR, Reynolds KL, Chen ST. Evaluating patterns of co-occurrence between cutaneous and noncutaneous immune-related adverse events after immune checkpoint inhibitor therapy. J Am Acad Dermatol. 2023 Jan; 88(1):246-249. PMID: 35577231.
    Citations:    Fields:    
  20. Falade AS, Reynolds KL, Zubiri L, Deshpande V, Fintelmann FJ, Dougan M, Mooradian MJ. Case Report: Fulminant Celiac Disease With Combination Immune Checkpoint Therapy. Front Immunol. 2022; 13:871452. PMID: 35493494; PMCID: PMC9049212.
    Citations:    Fields:    Translation:Humans
  21. Chang MS, Jacoby TV, Otto TS, Shah N, Asdourian MS, Thompson LL, Reynolds KL, Chen ST. Evaluating the treatment of cutaneous adverse events and adherence to National Comprehensive Cancer Network guidelines in patients receiving immune checkpoint inhibitors. Eur J Cancer. 2022 05; 166:21-23. PMID: 35259628.
    Citations:    Fields:    Translation:Humans
  22. Seethapathy H, Lee MD, Strohbehn IA, Efe O, Rusibamayila N, Chute DF, Colvin RB, Rosales IA, Fadden RM, Reynolds KL, Sullivan RJ, Kaufman HL, Jhaveri KD, Sise ME. Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib. Nephrol Dial Transplant. 2022 02 25; 37(3):507-514. PMID: 33355659; PMCID: PMC8875461.
    Citations: 1     Fields:    Translation:Humans
  23. Asdourian MS, Otto TS, Jacoby TV, Shah N, Thompson LL, Blum SM, Reynolds KL, Semenov YR, Lawrence DP, Sullivan RJ, Boland GM, Villani AC, Chen ST. Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma. J Am Acad Dermatol. 2022 Nov; 87(5):1147-1149. PMID: 35192899.
    Citations:    Fields:    
  24. Tang K, Seo J, Tiu BC, Le TK, Pahalyants V, Raval NS, Ugwu-Dike PO, Zubiri L, Naranbhai V, Carrington M, Gusev A, Reynolds KL, LeBoeuf NR, Asgari MM, Kwatra SG, Semenov YR. Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy. JAMA Dermatol. 2022 Feb 01; 158(2):189-193. PMID: 35019948; PMCID: PMC8756357.
    Citations: 6     Fields:    Translation:Humans
  25. Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, Carver J, Dent S, Ky B, Lyon AR, López-Fernández T, Fradley MG, Ganatra S, Curigliano G, Mitchell JD, Minotti G, Lang NN, Liu JE, Neilan TG, Nohria A, O'Quinn R, Pusic I, Porter C, Reynolds KL, Ruddy KJ, Thavendiranathan P, Valent P. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022 01 31; 43(4):280-299. PMID: 34904661; PMCID: PMC8803367.
    Citations: 4     Fields:    Translation:Humans
  26. Drobni ZD, Michielin O, Quinaglia T, Zlotoff DA, Zubiri L, Gilman HK, Supraja S, Merkely B, Muller V, Sullivan RJ, Reynolds KL, Pittet MJ, Jain RK, Neilan TG. Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors. Eur J Cancer. 2022 03; 163:108-118. PMID: 35065368; PMCID: PMC9618285.
    Citations: 1     Fields:    Translation:Humans
  27. Strohbehn IA, Street S, Chute D, Seethapathy H, Lee M, Seethapathy R, Drobni ZD, Rahma O, Neilan TG, Zubiri L, Reynolds K, Sise ME. Immune checkpoint inhibitor-induced thyroiditis is a risk factor for acute and chronic kidney dysfunction. Nephrol Dial Transplant. 2021 12 31; 37(1):187-189. PMID: 34383953; PMCID: PMC8719582.
    Citations: 1     Fields:    Translation:Humans
  28. Theodosakis N, Ugwu-Dike P, Pahalyants V, Reynolds K, Semenov Y. Title: Immune-checkpoint inhibitor therapy is underutilized in the US: A multi-institutional cohort analysis. Immunol Lett. 2022 04; 244:43-44. PMID: 34974035.
    Citations:    Fields:    Translation:Humans
  29. Seethapathy H, Rusibamayila N, Chute DF, Lee M, Strohbehn I, Zubiri L, Faje AT, Reynolds KL, Jhaveri KD, Sise ME. Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors. Nephrol Dial Transplant. 2021 12 02; 36(12):2241-2247. PMID: 33374011; PMCID: PMC8643613.
    Citations: 7     Fields:    Translation:Humans
  30. Burton LB, Eskian M, Guidon AC, Reynolds KL. A review of neurotoxicities associated with immunotherapy and a framework for evaluation. Neurooncol Adv. 2021 Nov; 3(Suppl 5):v108-v120. PMID: 34859238.
    Citations: 1     
  31. Naranbhai V, Pernat CA, Gavralidis A, St Denis KJ, Lam EC, Spring LM, Isakoff SJ, Farmer JR, Zubiri L, Hobbs GS, How J, Brunner AM, Fathi AT, Peterson JL, Sakhi M, Hambelton G, Denault EN, Mortensen LJ, Perriello LA, Bruno MN, Bertaux BY, Lawless AR, Jackson MA, Niehoff E, Barabell C, Nambu CN, Nakajima E, Reinicke T, Bowes C, Berrios-Mairena CJ, Ofoman O, Kirkpatrick GE, Thierauf JC, Reynolds K, Willers H, Beltran WG, Dighe AS, Saff R, Blumenthal K, Sullivan RJ, Chen YB, Kim A, Bardia A, Balazs AB, Iafrate AJ, Gainor JF. Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. J Clin Oncol. 2022 01 01; 40(1):12-23. PMID: 34752147; PMCID: PMC8683230.
    Citations: 12     Fields:    Translation:HumansCells
  32. Shi CR, Otto TS, Thompson LL, Chang MS, Reynolds KL, Chen ST. Methotrexate in the treatment of immune checkpoint blocker-induced bullous pemphigoid. Eur J Cancer. 2021 12; 159:34-37. PMID: 34731747.
    Citations:    Fields:    Translation:Humans
  33. Gong J, Drobni ZD, Alvi RM, Murphy SP, Sullivan RJ, Hartmann SE, Gilman HK, Lee H, Zubiri L, Raghu VK, Karp-Leaf RS, Zafar A, Zlotoff DA, Frigault MJ, Reynolds KL, Neilan TG. Immune checkpoint inhibitors for cancer and venous thromboembolic events. Eur J Cancer. 2021 Oct 15; 158:99-110. PMID: 34662835; PMCID: PMC9010482.
    Citations: 5     Fields:    
  34. Gupta S, Short SAP, Sise ME, Prosek JM, Madhavan SM, Soler MJ, Ostermann M, Herrmann SM, Abudayyeh A, Anand S, Glezerman I, Motwani SS, Murakami N, Wanchoo R, Ortiz-Melo DI, Rashidi A, Sprangers B, Aggarwal V, Malik AB, Loew S, Carlos CA, Chang WT, Beckerman P, Mithani Z, Shah CV, Renaghan AD, Seigneux S, Campedel L, Kitchlu A, Shin DS, Rangarajan S, Deshpande P, Coppock G, Eijgelsheim M, Seethapathy H, Lee MD, Strohbehn IA, Owen DH, Husain M, Garcia-Carro C, Bermejo S, Lumlertgul N, Seylanova N, Flanders L, Isik B, Mamlouk O, Lin JS, Garcia P, Kaghazchi A, Khanin Y, Kansal SK, Wauters E, Chandra S, Schmidt-Ott KM, Hsu RK, Tio MC, Sarvode Mothi S, Singh H, Schrag D, Jhaveri KD, Reynolds KL, Cortazar FB, Leaf DE. Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021 10; 9(10). PMID: 34625513; PMCID: PMC8496384.
    Citations: 9     Fields:    Translation:Humans
  35. Jacoby TV, Chang MS, Thompson LL, Foreman RK, Reynolds KL, Chen ST. Histopathologically-confirmed lichenoid eruptions from immune checkpoint inhibitor therapy: a retrospective cohort analysis. Br J Dermatol. 2021 12; 185(6):1254-1256. PMID: 34375436.
    Citations: 1     Fields:    Translation:Humans
  36. Seethapathy H, Street S, Strohbehn I, Lee M, Zhao SH, Rusibamayila N, Chute DF, Gao X, Michaelson MD, Rahma OE, Choueiri TK, McGregor B, Sonpavde G, Salabao C, Kaymakcalan MD, Wei X, Gupta S, Motwani S, Leaf DE, Reynolds KL, Sise ME. Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors. Eur J Cancer. 2021 11; 157:50-58. PMID: 34482189.
    Citations: 1     Fields:    Translation:Humans
  37. Zubiri L, Molina GE, Mooradian MJ, Cohen J, Durbin SM, Petrillo L, Boland GM, Juric D, Dougan M, Thomas MF, Faje AT, Rengarajan M, Guidon AC, Chen ST, Okin D, Medoff BD, Nasrallah M, Kohler MJ, Schoenfeld SR, Karp-Leaf RS, Sise ME, Neilan TG, Zlotoff DA, Farmer JR, Bardia A, Sullivan RJ, Blum SM, Semenov YR, Villani AC, Reynolds KL. Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. J Immunother Cancer. 2021 09; 9(9). PMID: 34544895; PMCID: PMC8454442.
    Citations: 1     Fields:    Translation:Humans
  38. Guidon AC, Burton LB, Chwalisz BK, Hillis J, Schaller TH, Amato AA, Betof Warner A, Brastianos PK, Cho TA, Clardy SL, Cohen JV, Dietrich J, Dougan M, Doughty CT, Dubey D, Gelfand JM, Guptill JT, Johnson DB, Juel VC, Kadish R, Kolb N, LeBoeuf NR, Linnoila J, Mammen AL, Martinez-Lage M, Mooradian MJ, Naidoo J, Neilan TG, Reardon DA, Rubin KM, Santomasso BD, Sullivan RJ, Wang N, Woodman K, Zubiri L, Louv WC, Reynolds KL. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2021 07; 9(7). PMID: 34281989.
    Citations: 18     Fields:    Translation:Humans
  39. Lee DJ, Lee HJ, Farmer JR, Reynolds KL. Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors. Curr Cardiol Rep. 2021 07 01; 23(8):98. PMID: 34196833.
    Citations: 7     Fields:    Translation:Humans
  40. Reynolds KL, Arora S, Elayavilli RK, Louv WC, Schaller TH, Khandelwal A, Rothenberg M, Khozin S, Guidon AC, Dougan M, Zubiri L, Petrillo L, Sise ME, Villani AC, Johnson DB, Rahma O, Sharon E. Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data. J Immunother Cancer. 2021 07; 9(7). PMID: 34215691.
    Citations: 5     Fields:    Translation:Humans
  41. Chute DF, Zhao S, Strohbehn IA, Rusibamayila N, Seethapathy H, Lee M, Zubiri L, Gupta S, Leaf DE, Rahma O, Drobni ZD, Neilan TG, Reynolds KL, Sise ME. Incidence and Predictors of CKD and Estimated GFR Decline in Patients Receiving Immune Checkpoint Inhibitors. Am J Kidney Dis. 2022 01; 79(1):134-137. PMID: 34174363; PMCID: PMC8855486.
    Citations: 3     Fields:    Translation:Humans
  42. Drobni ZD, Murphy SP, Alvi RM, Lee C, Gong J, Mosarla RC, Rambarat PK, Hartmann SB, Gilman HK, Zubiri L, Raghu VK, Sullivan RJ, Zafar A, Zlotoff DA, Sise ME, Guidon AC, Reynolds KL, Dougan M, Neilan TG. Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors. Immunother Adv. 2021 Jan; 1(1):ltab014. PMID: 34541581; PMCID: PMC8444991.
    Citations: 2     
  43. Pisuchpen N, Durbin SM, Mooradian MJ, Fintelmann FJ, Reynolds KL, Dougan M, Kambadakone A. Multi-detector computed tomography (MDCT)-based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis. Eur Radiol. 2021 Dec; 31(12):8868-8878. PMID: 34081152.
    Citations:    Fields:    Translation:Humans
  44. Gong J, Drobni ZD, Zafar A, Quinaglia T, Hartmann S, Gilman HK, Raghu VK, Gongora C, Sise ME, Alvi RM, Zubiri L, Nohria A, Sullivan R, Reynolds KL, Zlotoff D, Neilan TG. Pericardial disease in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021 06; 9(6). PMID: 34145031.
    Citations: 2     Fields:    Translation:Humans
  45. Frayberg M, Yung A, Zubiri L, Zlotoff DA, Reynolds KL. What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications. Curr Treat Options Oncol. 2021 05 26; 22(6):53. PMID: 34037918.
    Citations: 1     Fields:    Translation:Humans
  46. Street S, Chute D, Strohbehn I, Zhao S, Rengarajan M, Faje A, Seethapathy H, Lee M, Seethapathy R, Drobni Z, Rahma O, Neilan TG, Sullivan RJ, Villani AC, Zubiri L, Mooradian MJ, Reynolds KL, Sise ME. The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: a retrospective cohort study of 6596 patients. Ann Oncol. 2021 08; 32(8):1050-1051. PMID: 34020034; PMCID: PMC8814352.
    Citations: 8     Fields:    Translation:Humans
  47. Zubiri L, Rosovsky RP, Mooradian MJ, Piper-Vallillo AJ, Gainor JF, Sullivan RJ, Marte D, Boland GM, Gao X, Hochberg EP, Ryan DP, McEwen C, Mai M, Sharova T, Soumerai TE, Bardia A, Reynolds KL. Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center. Oncologist. 2021 08; 26(8):e1427-e1433. PMID: 33932247; PMCID: PMC8242879.
    Citations: 1     Fields:    Translation:HumansCellsPHPublic Health
  48. Thompson LL, Li EB, Krasnow NA, Chang MS, Said JT, Molina GE, Polyakov NJ, Yoon J, Dee EC, Huang K, Blum AE, Kuchroo JR, Hinton AN, Reynolds KL, Chen ST. Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity. Br J Dermatol. 2021 09; 185(3):627-635. PMID: 33733456.
    Citations: 4     Fields:    Translation:Humans
  49. Bui AN, Tyan K, Giobbie-Hurder A, Klein IA, Manos MP, Zubiri L, Reynolds K, Grover S, Weinhouse GL, Ott PA, LeBoeuf NR, Rahma O. Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors. J Immunother Precis Oncol. 2021 May; 4(2):35-44. PMID: 35663537; PMCID: PMC9153254.
    Citations: 2     
  50. Klein IA, Rosenberg SM, Reynolds KL, Zubiri L, Rosovsky R, Piper-Vallillo AJ, Gao X, Boland G, Bardia A, Gaither R, Freeman H, Kirkner GJ, Rhee C, Klompas M, Baker MA, Wadleigh M, Winer EP, Kotton CN, Partridge AH. Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19. Oncologist. 2021 08; 26(8):685-693. PMID: 33856099; PMCID: PMC8251362.
    Citations: 1     Fields:    Translation:HumansCells
  51. Thompson LL, Krasnow NA, Chang MS, Yoon J, Li EB, Polyakov NJ, Molina GE, Said JT, Huang K, Kuchroo JR, Hinton AN, Reynolds KL, Chen ST. Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer. JAMA Dermatol. 2021 05 01; 157(5):577-582. PMID: 33760001; PMCID: PMC7992016.
    Citations: 6     Fields:    Translation:Humans
  52. Molina GE, Otto TS, Yu Z, Foreman RK, Reynolds KL, Chen ST. Response to: "Immune checkpoint inhibitor-related Stevens-Johnson syndrome/toxic epidermal necrolysis-like reactions". J Am Acad Dermatol. 2021 08; 85(2):e111-e112. PMID: 33878410.
    Citations:    Fields:    Translation:Humans
  53. Klebanov N, Pahalyants V, Murphy WS, Theodosakis N, Zubiri L, Klevens RM, Kwatra SG, Lilly E, Reynolds KL, Semenov YR. Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors. Oncologist. 2021 05; 26(5):e898-e901. PMID: 33783099; PMCID: PMC8100539.
    Citations: 6     Fields:    Translation:HumansCells
  54. Wongvibulsin S, Pahalyants V, Kalinich M, Murphy W, Yu KH, Wang F, Chen ST, Reynolds K, Kwatra SG, Semenov YR. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis. J Am Acad Dermatol. 2022 03; 86(3):563-572. PMID: 33819538.
    Citations: 5     Fields:    Translation:Humans
  55. Lee MD, Seethapathy H, Strohbehn IA, Zhao SH, Boland GM, Fadden R, Sullivan R, Reynolds KL, Sise ME. Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study. J Immunother Cancer. 2021 04; 9(4). PMID: 33849926; PMCID: PMC8051410.
    Citations: 3     Fields:    Translation:Humans
  56. Molina GE, Zubiri L, Cohen JV, Durbin SM, Petrillo L, Allen IM, Murciano-Goroff YR, Dougan M, Thomas MF, Faje AT, Rengarajan M, Guidon AC, Chen ST, Okin D, Medoff BD, Nasrallah M, Kohler MJ, Schoenfeld SR, Karp Leaf RS, Sise ME, Neilan TG, Zlotoff DA, Farmer JR, Mooradian MJ, Bardia A, Mai M, Sullivan RJ, Semenov YR, Villani AC, Reynolds KL. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist. 2021 06; 26(6):514-522. PMID: 33655682; PMCID: PMC8176966.
    Citations: 5     Fields:    Translation:Humans
  57. Thavendiranathan P, Zhang L, Zafar A, Drobni ZD, Mahmood SS, Cabral M, Awadalla M, Nohria A, Zlotoff DA, Thuny F, Heinzerling LM, Barac A, Sullivan RJ, Chen CL, Gupta D, Kirchberger MC, Hartmann SE, Weinsaft JW, Gilman HK, Rizvi MA, Kovacina B, Michel C, Sahni G, González-Mansilla A, Calles A, Fernández-Avilés F, Mahmoudi M, Reynolds KL, Ganatra S, Gavira JJ, González NS, García de Yébenes Castro M, Kwong RY, Jerosch-Herold M, Coelho-Filho OR, Afilalo J, Zataraín-Nicolás E, Baksi AJ, Wintersperger BJ, Calvillo-Arguelles O, Ederhy S, Yang EH, Lyon AR, Fradley MG, Neilan TG. Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis. J Am Coll Cardiol. 2021 03 30; 77(12):1503-1516. PMID: 33766256; PMCID: PMC8442989.
    Citations: 19     Fields:    Translation:Humans
  58. Kalinich M, Murphy W, Wongvibulsin S, Pahalyants V, Yu KH, Lu C, Wang F, Zubiri L, Naranbhai V, Gusev A, Kwatra SG, Reynolds KL, Semenov YR. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. J Immunother Cancer. 2021 03; 9(3). PMID: 33789879.
    Citations: 5     Fields:    Translation:Humans
  59. Zlotoff DA, Hassan MZO, Zafar A, Alvi RM, Awadalla M, Mahmood SS, Zhang L, Chen CL, Ederhy S, Barac A, Banerji D, Jones-O'Connor M, Murphy SP, Armanious M, Forrestal BJ, Kirchberger MC, Coelho-Filho OR, Rizvi MA, Sahni G, Mandawat A, Tocchetti CG, Hartmann S, Gilman HK, Zatarain-Nicolás E, Mahmoudi M, Gupta D, Sullivan R, Ganatra S, Yang EH, Heinzerling LM, Thuny F, Zubiri L, Reynolds KL, Cohen JV, Lyon AR, Groarke J, Thavendiranathan P, Nohria A, Fradley MG, Neilan TG. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. J Immunother Cancer. 2021 03; 9(3). PMID: 33653803.
    Citations: 6     Fields:    Translation:Humans
  60. Leppelmann KS, Mooradian MJ, Ganguli S, Uppot RN, Yamada K, Irani Z, Wehrenberg-Klee EP, Zubiri L, Reynolds KL, Arellano RS, Hirsch JA, Sullivan RJ, Fintelmann FJ. Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety Analysis. J Vasc Interv Radiol. 2021 02; 32(2):187-195. PMID: 33353814.
    Citations: 5     Fields:    Translation:Humans
  61. Zhang L, Reynolds KL, Lyon AR, Palaskas N, Neilan TG. The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer. JACC CardioOncol. 2021 Mar; 3(1):35-47. PMID: 33842895.
    Citations: 14     
  62. Rogiers A, Pires da Silva I, Tentori C, Tondini CA, Grimes JM, Trager MH, Nahm S, Zubiri L, Manos M, Bowling P, Elkrief A, Papneja N, Vitale MG, Rose AAN, Borgers JSW, Roy S, Mangana J, Pimentel Muniz T, Cooksley T, Lupu J, Vaisman A, Saibil SD, Butler MO, Menzies AM, Carlino MS, Erdmann M, Berking C, Zimmer L, Schadendorf D, Pala L, Queirolo P, Posch C, Hauschild A, Dummer R, Haanen J, Blank CU, Robert C, Sullivan RJ, Ascierto PA, Miller WH, Stephen Hodi F, Suijkerbuijk KPM, Reynolds KL, Rahma OE, Lorigan PC, Carvajal RD, Lo S, Mandala M, Long GV. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. J Immunother Cancer. 2021 01; 9(1). PMID: 33468556; PMCID: PMC7817383.
    Citations: 16     Fields:    Translation:HumansCells
  63. Drobni ZD, Zafar A, Zubiri L, Zlotoff DA, Alvi RM, Lee C, Hartmann S, Gilman HK, Villani AC, Nohria A, Groarke JD, Sullivan RJ, Reynolds KL, Zhang L, Neilan TG. Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor-Associated Myocarditis. J Am Heart Assoc. 2020 12; 9(23):e018306. PMID: 33190570.
    Citations: 10     Fields:    Translation:HumansCells
  64. Piper-Vallillo AJ, Mooradian MJ, Meador CB, Yeap BY, Peterson J, Sakhi M, Do A, Zubiri L, Stevens S, Vaughn J, Goodwin K, Gavralidis A, Willers H, Miller A, Farago A, Piotrowska Z, Lin JJ, Dagogo-Jack I, Lennes IT, Sequist LV, Temel JS, Heist RS, Digumarthy S, Reynolds KL, Gainor JF. Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations. JTO Clin Res Rep. 2021 Jan; 2(1):100124. PMID: 33205053; PMCID: PMC7659804.
    Citations: 3     
  65. Durbin SM, Zubiri L, Niemierko A, Bardia A, Sullivan RJ, McEwen C, Mulvey TM, Allen IM, Lawrence DP, Cohen JV, Hochberg EP, Ryan DP, Petrillo LA, Reynolds KL. Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting. Oncologist. 2021 01; 26(1):49-55. PMID: 33044765; PMCID: PMC7794195.
    Citations: 5     Fields:    Translation:Humans
  66. Thompson LL, Katznelson E, Leet DE, Durbin SM, Yoon J, Reynolds KL, Dougan ML, Chen ST. Impact of systemic corticosteroids on survival outcomes in immune checkpoint inhibitor-induced gastroenterocolitis. Eur J Cancer. 2021 01; 142:143-146. PMID: 33268234.
    Citations: 2     Fields:    Translation:Humans
  67. Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, Mosarla RC, Lee C, Zlotoff DA, Raghu VK, Hartmann SE, Gilman HK, Gong J, Zubiri L, Sullivan RJ, Reynolds KL, Mayrhofer T, Zhang L, Hoffmann U, Neilan TG. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation. 2020 12 15; 142(24):2299-2311. PMID: 33003973.
    Citations: 52     Fields:    Translation:Humans
  68. Watson TR, Gao X, Reynolds KL, Kong CY. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US. JAMA Netw Open. 2020 10 01; 3(10):e2016144. PMID: 33052401.
    Citations: 7     Fields:    Translation:Humans
  69. Durbin SM, Mooradian MJ, Fintelmann FJ, Zubiri L, Chute DF, Kambadakone A, Pisuchpen N, Reynolds KL, Dougan M. Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis. J Immunother Cancer. 2020 10; 8(2). PMID: 33033184.
    Citations: 2     Fields:    Translation:Humans
  70. Reynolds KL, Klempner SJ, Parikh A, Hochberg EP, Michaelson MD, Mooradian MJ, Lee RJ, Soumerai TE, Hobbs G, Piotrowska Z, Sykes DB, Farago AF, Bardia A, Rosovsky RP, Ryan DP. The Art of Oncology: COVID-19 Era. Oncologist. 2020 11; 25(11):997-1000g. PMID: 32697887.
    Citations: 4     Fields:    Translation:HumansCells
  71. Cohen JV, Dougan M, Zubiri L, Reynolds KL, Sullivan RJ, Misdraji J. Liver biopsy findings in patients on immune checkpoint inhibitors. Mod Pathol. 2021 02; 34(2):426-437. PMID: 32884128.
    Citations: 10     Fields:    Translation:Humans
  72. Molina GE, Reynolds KL, Chen ST. Diagnostic and therapeutic differences between immune checkpoint inhibitor-induced and idiopathic bullous pemphigoid: a cross-sectional study. Br J Dermatol. 2020 12; 183(6):1126-1128. PMID: 32531797.
    Citations: 5     Fields:    Translation:Humans
  73. Johnson DB, Reynolds KL, Sullivan RJ, Balko JM, Patrinely JR, Cappelli LC, Naidoo J, Moslehi JJ. Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. Lancet Oncol. 2020 08; 21(8):e398-e404. PMID: 32758477.
    Citations: 26     Fields:    Translation:Humans
  74. Seethapathy H, Zhao S, Strohbehn IA, Lee M, Chute DF, Bates H, Molina GE, Zubiri L, Gupta S, Motwani S, Leaf DE, Sullivan RJ, Rahma O, Blumenthal KG, Villani AC, Reynolds KL, Sise ME. Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors. Kidney Int Rep. 2020 Oct; 5(10):1700-1705. PMID: 33102962; PMCID: PMC7569697.
    Citations: 10     
  75. Zhang L, Zlotoff DA, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F, Zubiri L, Chen CL, Sullivan RJ, Alvi RM, Rokicki A, Murphy SP, Jones-O'Connor M, Heinzerling LM, Barac A, Forrestal BJ, Yang EH, Gupta D, Kirchberger MC, Shah SP, Rizvi MA, Sahni G, Mandawat A, Mahmoudi M, Ganatra S, Ederhy S, Zatarain-Nicolas E, Groarke JD, Tocchetti CG, Lyon AR, Thavendiranathan P, Cohen JV, Reynolds KL, Fradley MG, Neilan TG. Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. Circulation. 2020 06 16; 141(24):2031-2034. PMID: 32539614; PMCID: PMC7301778.
    Citations: 45     Fields:    Translation:Humans
  76. El-Jawahri A, Traeger L, Greer JA, Vanbenschoten O, Markovitz N, Cashavelly B, Tata LA, Nipp RD, Reynolds KL, Goyal L, Bhatt S, Fishman S, Horick N, Li Z, Volandes A, Temel JS. Randomized trial of a hospice video educational tool for patients with advanced cancer and their caregivers. Cancer. 2020 08 01; 126(15):3569-3578. PMID: 32508043.
    Citations: 1     Fields:    Translation:Humans
  77. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020 06 20; 395(10241):1907-1918. PMID: 32473681.
    Citations: 626     Fields:    Translation:HumansCellsPHPublic Health
  78. Strohbehn IA, Lee M, Seethapathy H, Chute D, Rahma O, Guidon A, Neilan TG, Zlotoff DA, Okin D, Rengarajan M, Reynolds K, Sise ME. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients on Dialysis: A Retrospective Case Series. Am J Kidney Dis. 2020 08; 76(2):299-302. PMID: 32417401.
    Citations: 5     Fields:    Translation:Humans
  79. Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F, Zlotoff DA, Murphy SP, Stone JR, Golden DLA, Alvi RM, Rokicki A, Jones-O'Connor M, Cohen JV, Heinzerling LM, Mulligan C, Armanious M, Barac A, Forrestal BJ, Sullivan RJ, Kwong RY, Yang EH, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Moslehi JJ, Coelho-Filho OR, Ganatra S, Rizvi MA, Sahni G, Tocchetti CG, Mercurio V, Mahmoudi M, Lawrence DP, Reynolds KL, Weinsaft JW, Baksi AJ, Ederhy S, Groarke JD, Lyon AR, Fradley MG, Thavendiranathan P, Neilan TG. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. 2020 05 07; 41(18):1733-1743. PMID: 32112560; PMCID: PMC7205467.
    Citations: 68     Fields:    Translation:Humans
  80. Sullivan RJ, Johnson DB, Rini BI, Neilan TG, Lovly CM, Moslehi JJ, Reynolds KL. COVID-19 and immune checkpoint inhibitors: initial considerations. J Immunother Cancer. 2020 05; 8(1). PMID: 32434790.
    Citations: 27     Fields:    Translation:HumansPHPublic Health
  81. Seethapathy H, Bates H, Chute DF, Strohbehn I, Strohbehn S, Fadden RM, Reynolds KL, Cohen JV, Sullivan RJ, Sise ME. Acute Kidney Injury Following Encorafenib and Binimetinib for Metastatic Melanoma. Kidney Med. 2020 May-Jun; 2(3):373-375. PMID: 32734258.
    Citations: 1     
  82. Darnell EP, Mooradian MJ, Baruch EN, Yilmaz M, Reynolds KL. Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. Curr Oncol Rep. 2020 03 21; 22(4):39. PMID: 32200442.
    Citations: 42     Fields:    Translation:Humans
  83. Molina GE, Yu Z, Foreman RK, Reynolds KL, Chen ST. Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: A multicenter case series. J Am Acad Dermatol. 2020 Nov; 83(5):1475-1477. PMID: 32199891.
    Citations: 1     Fields:    Translation:Humans
  84. Reynolds KL, Sullivan RJ, Fintelmann FJ, Mansour MK, England J. Case 9-2020: A 64-Year-Old Man with Shortness of Breath, Cough, and Hypoxemia. N Engl J Med. 2020 Mar 19; 382(12):1150-1159. PMID: 32187473.
    Citations: 1     Fields:    Translation:Humans
  85. Dubey D, David WS, Reynolds KL, Chute DF, Clement NF, Cohen JV, Lawrence DP, Mooradian MJ, Sullivan RJ, Guidon AC. Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. Ann Neurol. 2020 05; 87(5):659-669. PMID: 32086972.
    Citations: 36     Fields:    Translation:Humans
  86. Petrillo LA, El-Jawahri A, Nipp RD, Lichtenstein MRL, Durbin SM, Reynolds KL, Greer JA, Temel JS, Gainor JF. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors. Cancer. 2020 05 15; 126(10):2288-2295. PMID: 32142165.
    Citations: 11     Fields:    Translation:Humans
  87. Awadalla M, Mahmood SS, Groarke JD, Hassan MZO, Nohria A, Rokicki A, Murphy SP, Mercaldo ND, Zhang L, Zlotoff DA, Reynolds KL, Alvi RM, Banerji D, Liu S, Heinzerling LM, Jones-O'Connor M, Bakar RB, Cohen JV, Kirchberger MC, Sullivan RJ, Gupta D, Mulligan CP, Shah SP, Ganatra S, Rizvi MA, Sahni G, Tocchetti CG, Lawrence DP, Mahmoudi M, Devereux RB, Forrestal BJ, Mandawat A, Lyon AR, Chen CL, Barac A, Hung J, Thavendiranathan P, Picard MH, Thuny F, Ederhy S, Fradley MG, Neilan TG. Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. J Am Coll Cardiol. 2020 02 11; 75(5):467-478. PMID: 32029128; PMCID: PMC7067226.
    Citations: 51     Fields:    Translation:Humans
  88. Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, Smith BL, Alexander B, Moy B, Isakoff SJ, Parmigiani G, Trippa L, Bardia A. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res. 2020 06 15; 26(12):2838-2848. PMID: 32046998.
    Citations: 91     Fields:    Translation:Humans
  89. Gupta S, Seethapathy H, Strohbehn IA, Frigault MJ, O'Donnell EK, Jacobson CA, Motwani SS, Parikh SM, Curhan GC, Reynolds KL, Leaf DE, Sise ME. Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. Am J Kidney Dis. 2020 07; 76(1):63-71. PMID: 31973908.
    Citations: 20     Fields:    Translation:Humans
  90. Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, Murakami N, Herrmann SM, Manohar S, Shirali AC, Kitchlu A, Shirazian S, Assal A, Vijayan A, Renaghan AD, Ortiz-Melo DI, Rangarajan S, Malik AB, Hogan JJ, Dinh AR, Shin DS, Marrone KA, Mithani Z, Johnson DB, Hosseini A, Uprety D, Sharma S, Gupta S, Reynolds KL, Sise ME, Leaf DE. Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. J Am Soc Nephrol. 2020 02; 31(2):435-446. PMID: 31896554; PMCID: PMC7003302.
    Citations: 69     Fields:    Translation:Humans
  91. Qualls D, Seethapathy H, Bates H, Tajmir S, Heidari P, Endres P, Reynolds K, Lawrence D, Sise M. Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis. J Immunother Cancer. 2019 12 21; 7(1):356. PMID: 31864416.
    Citations: 7     Fields:    Translation:Humans
  92. Zubiri L, Allen IM, Taylor MS, Guidon AC, Chen ST, Schoenfeld SR, Neilan TG, Sise ME, Mooradian MJ, Rubin KM, Leaf RK, Parikh AR, Faje A, Gainor JF, Cohen JV, Fintelmann FJ, Kohler MJ, Dougan M, Reynolds KL. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2020 03; 25(3):e398-e404. PMID: 32162817; PMCID: PMC7066708.
    Citations: 3     Fields:    Translation:Humans
  93. Zubiri L, Allen IM, Taylor MS, Guidon AC, Chen ST, Schoenfeld SR, Neilan TG, Sise ME, Mooradian MJ, Rubin KM, Leaf RK, Parikh AR, Faje A, Gainor JF, Cohen JV, Fintelmann FJ, Kohler MJ, Dougan M, Reynolds KL. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2019 Nov 21. PMID: 31754069.
    Citations:    
  94. Schoenfeld SR, Aronow ME, Leaf RK, Dougan M, Reynolds KL. Diagnosis and Management of Rare Immune-Related Adverse Events. Oncologist. 2020 01; 25(1):6-14. PMID: 31694890; PMCID: PMC6964128.
    Citations: 11     Fields:    Translation:Humans
  95. Seethapathy H, Zhao S, Chute DF, Zubiri L, Oppong Y, Strohbehn I, Cortazar FB, Leaf DE, Mooradian MJ, Villani AC, Sullivan RJ, Reynolds K, Sise ME. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. Clin J Am Soc Nephrol. 2019 12 06; 14(12):1692-1700. PMID: 31672794.
    Citations: 62     Fields:    Translation:Humans
  96. Chen ST, Molina GE, Lo JA, Durbin S, Cohen JV, Reynolds KL, Kroshinsky D. Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related adverse events: A retrospective cohort study. J Am Acad Dermatol. 2020 04; 82(4):994-996. PMID: 31560981.
    Citations: 8     Fields:    Translation:Humans
  97. Criss SD, Mooradian MJ, Watson TR, Gainor JF, Reynolds KL, Kong CY. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States. JAMA Netw Open. 2019 09 04; 2(9):e1911952. PMID: 31553470.
    Citations: 19     Fields:    Translation:Humans
  98. Faje A, Reynolds K, Zubiri L, Lawrence D, Cohen JV, Sullivan RJ, Nachtigall L, Tritos N. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol. 2019 Sep; 181(3):211-219. PMID: 31176301.
    Citations: 34     Fields:    Translation:Humans
  99. Dubey D, David WS, Amato AA, Reynolds KL, Clement NF, Chute DF, Cohen JV, Lawrence DP, Mooradian MJ, Sullivan RJ, Guidon AC. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology. 2019 09 10; 93(11):e1093-e1103. PMID: 31405908.
    Citations: 32     Fields:    Translation:Humans
  100. Molina GE, Allen IM, Hughes MS, Zubiri L, Lee H, Mooradian MJ, Reynolds KL, Dougan M, Chen ST. Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study. J Am Acad Dermatol. 2020 03; 82(3):743-746. PMID: 31349048.
    Citations: 5     Fields:    Translation:Humans
  101. Hughes MS, Zheng H, Zubiri L, Molina GE, Chen ST, Mooradian MJ, Allen IM, Reynolds KL, Dougan M. Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control. Cancer Med. 2019 Sep; 8(11):4986-4999. PMID: 31286682.
    Citations: 15     Fields:    Translation:Humans
  102. Cole S, Zibelman M, Bertino E, Yucebay F, Reynolds K. Managing Immuno-Oncology Toxicity: Top 10 Innovative Institutional Solutions. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:96-104. PMID: 31099682.
    Citations: 11     Fields:    Translation:Humans
  103. Sise ME, Seethapathy H, Reynolds KL. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review. Oncologist. 2019 06; 24(6):735-742. PMID: 30902916.
    Citations: 14     Fields:    Translation:Humans
  104. Leaf RK, Ferreri C, Rangachari D, Mier J, Witteles W, Ansstas G, Anagnostou T, Zubiri L, Piotrowska Z, Oo TH, Iberri D, Yarchoan M, Salama AKS, Johnson DB, Leavitt AD, Rahma OE, Reynolds KL, Leaf DE. Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. Am J Hematol. 2019 05; 94(5):563-574. PMID: 30790338; PMCID: PMC9552038.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  105. Criss SD, Mooradian MJ, Sheehan DF, Zubiri L, Lumish MA, Gainor JF, Reynolds KL, Kong CY. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System. JAMA Oncol. 2019 03 01; 5(3):358-365. PMID: 30543349.
    Citations: 16     Fields:    Translation:Humans
  106. Awadalla M, Golden DLA, Mahmood SS, Alvi RM, Mercaldo ND, Hassan MZO, Banerji D, Rokicki A, Mulligan C, Murphy SPT, Jones-O'Connor M, Cohen JV, Heinzerling LM, Armanious M, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Rizvi MA, Sahni G, Lyon AR, Tocchetti CG, Mercurio V, Thuny F, Ederhy S, Mahmoudi M, Lawrence DP, Groarke JD, Nohria A, Fradley MG, Reynolds KL, Neilan TG. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. J Immunother Cancer. 2019 02 22; 7(1):53. PMID: 30795818; PMCID: PMC6387531.
    Citations: 29     Fields:    Translation:HumansPHPublic Health
  107. Reynolds KL, Guidon AC. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature. Oncologist. 2019 04; 24(4):435-443. PMID: 30482825; PMCID: PMC6459240.
    Citations: 21     Fields:    Translation:Humans
  108. Chu JN, Choi J, Ostvar S, Torchia JA, Reynolds KL, Tramontano A, Gainor JF, Chung DC, Clark JW, Hur C. Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Cancer. 2019 01 15; 125(2):278-289. PMID: 30343509.
    Citations: 8     Fields:    Translation:HumansCells
  109. Mooradian MJ, Nasrallah M, Gainor JF, Reynolds KL, Cohen JV, Lawrence DP, Miloslavsky EM, Kohler MJ, Sullivan RJ, Schoenfeld SR. Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience. Semin Arthritis Rheum. 2019 06; 48(6):1127-1132. PMID: 30409415.
    Citations: 27     Fields:    Translation:Humans
  110. Spring L, Niemierko A, Haddad S, Yuen M, Comander A, Reynolds K, Shin J, Bahn A, Brachtel E, Specht M, Smith BL, Taghian A, Jimenez R, Peppercorn J, Isakoff SJ, Moy B, Bardia A. Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer. Breast Cancer Res Treat. 2018 Dec; 172(3):733-740. PMID: 30220055; PMCID: PMC6235701.
    Citations: 4     Fields:    Translation:Humans
  111. Mahmood SS, Sullivan RJ, Reynolds KL, Neilan TG. Reply: Immunosuppression Does Not Reduce Antitumor Efficacy. J Am Coll Cardiol. 2018 08 07; 72(6):702. PMID: 30072007; PMCID: PMC6190803.
    Citations: 1     Fields:    Translation:Humans
  112. Reynolds K, Thomas M, Dougan M. Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade. Oncologist. 2018 09; 23(9):991-997. PMID: 29853659.
    Citations: 34     Fields:    Translation:Humans
  113. Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Awadalla M, Hassan MZO, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Lawrence DP, Groarke JD, Neilan TG. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018 04 24; 71(16):1755-1764. PMID: 29567210; PMCID: PMC6196725.
    Citations: 361     Fields:    Translation:Humans
  114. Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang YJ. A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer. 2017 Sep 12; 17(1):646. PMID: 28899363.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  115. Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ, Moy B, Bardia A. Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016 Nov 01; 2(11):1477-1486. PMID: 27367583; PMCID: PMC5738656.
    Citations: 94     Fields:    Translation:Humans
  116. Reynolds K, Sarangi S, Bardia A, Dizon DS. Precision medicine and personalized breast cancer: combination pertuzumab therapy. Pharmgenomics Pers Med. 2014; 7:95-105. PMID: 24715764.
    Citations: 4     
  117. Reynolds KL, Higgins MJ. Endocrine therapy for breast cancer: a tough pill to swallow. Menopause. 2013 Jul; 20(7):714-6. PMID: 23760435.
    Citations: 1     Fields:    Translation:Humans
  118. Liu Y, Pérez M, Aft RL, Massman K, Robinson E, Myles S, Schootman M, Gillanders WE, Jeffe DB. Accuracy of perceived risk of recurrence among patients with early-stage breast cancer. Cancer Epidemiol Biomarkers Prev. 2010 Mar; 19(3):675-80. PMID: 20160274.
    Citations: 26     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Reynolds's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (262)
Explore
_
Co-Authors (181)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.